Novel biologic therapies for thymic epithelial tumors.

Novel Treatments for Thymoma and Thymic Carcinoma. Front Oncol (2015) 0.75

In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. J Nucl Med (1998) 1.64

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol (1994) 1.51

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res (2009) 1.42

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol (2014) 1.40

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36

Chemotherapy for invasive thymoma. A 13-year experience. Cancer (1991) 1.28

KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol (2004) 1.28

Optimal therapy for thymoma. J Med Invest (2008) 1.25

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer (2010) 1.23

Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol (2004) 1.17

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol (2009) 1.05

Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer (2010) 1.04

Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol (2002) 0.95

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer (2015) 0.92

Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer (2002) 0.91

Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. Chest (2009) 0.87

Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol (2011) 0.85

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. Target Oncol (2012) 0.82